1 / 10

Drug of Abuse Testing Global Market Analysis

Apelo Consulting has released a report on u201cDrug of Abuse Testing Market (By Product Type, Sample Type, Drug Type, End Users, Region), Regulatory Status, Company Profiles and Market Dynamics u2013 Global Forecast to 2032u201d

ApeloConsulting
Download Presentation

Drug of Abuse Testing Global Market Analysis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Global Drug of Abuse Testing Market Analysis 2024-2032 Comprehensive Report Market size 2024: US$ 7,391M | Forecast 2032:US$ 11,715M Prepared by Apelo Consulting 1 Global Drug of Abuse Testing Market Analysis Apelo Consulting

  2. Executive Summary Market growth, global burden, and key drivers (2024–2032) GLOBAL USERS USE DISORDERS 296M Used illicit substances in past year 39.5M Living with drug-use disorders Key Growth Drivers Stringent regulatory mandates requiring drug testing Rising alcohol/substance mortality Expanded workplace and institutional testing protocols Increased illicit production/trafficking and enforcement efforts Government initiatives to combat substance abuse abuse and drug-related Note: Drug use associated with higher incidence of HIV, hepatitis, and tuberculosis; testing enables medical intervention, monitoring, and policy compliance. Apelo Consulting | Page 2

  3. What is Liquid Biopsy? Definition, biological matrices, purposes, and public health context What is drug of abuse testing? Identification of illegal or misused prescription substances using biological samples, enabling timely care and policy compliance. Biological matrices Primary purposes Medical intervention and clinical decision support Monitoring substance use and treatment adherence Compliance with legal, workplace, and institutional policies Testing workflow Note: Urine is most commonly used for screening due to metabolite detection; hair supports up to ~90-day detection windows. Public health context: Drug use is associated with higher incidence of HIV, hepatitis, and tuberculosis. Effective testing helps mitigate these risks through early detection and intervention. Apelo Consulting | Page 3 Apelo Consulting | Page 3

  4. Segmentation by Product Type Key insight: Consumables are the largest segment Consumables vs Equipment and equipment breakdown Consumables lead due to ease of use and rapid turnaround compared with equipment. Immunoassay analyzers dominate equipment as a convenient screening method across matrices. Apelo Consulting | Page 4

  5. Segmentation by Sample Type Urine (largest) • Blood • Oral fluids • Hair • Sweat Urine Largest; rich in metabolites—standard for screening. Blood Second; used in clinical/confirmatory contexts. Oral fluids Convenient; observed collection reduces tampering. Hair Detects long-term use; up to ~90-day window. Sweat Niche; supports continuous/extended monitoring. Insight: Urine dominates due to metabolite detection; hair supports up to ~90-day window. Apelo Consulting | Page 5

  6. Segmentation by Drug Type Urine (largest) • Blood • Oral fluids • Hair • Sweat Insight: Cannabis leads; opioids second; alcohol is significant globally. Apelo Consulting | Page 6

  7. Segmentation by End Users Employment testing (largest) • Criminal justice (second) • Lab-based • Professional POC • Home OTC Insight: Employment testing leads; criminal justice is the second-largest segment. Apelo Consulting | Page 7

  8. Regional Market Analysis North America leads; Europe second; strong growth across APAC and MEA Insight: North America is largest; Europe next; APAC rising on stricter rules; MEA accelerating with awareness initiatives. Apelo Consulting | Page 8

  9. Market Dynamics: Drivers & Challenges Factors shaping demand for drug of abuse testing Key Drivers Key Challenges Progressive legalization/decriminalization of certain substances in some regions. Regulatory, epidemiological, and institutional forces Constraints on market expansion Regulatory mandates requiring workplace and institutional drug testing. Rising alcohol and substance abuse prevalence globally. Shortage of skilled professionals to perform and interpret tests accurately. Increasing drug-related mortality intensifying screening needs. Implication: Strong, regulation-led demand persists; workforce development and evolving legal frameworks are critical watch areas. Expansion of workplace and institutional testing programs. Growth in global production and trafficking of illicit drugs. Government initiatives to combat substance abuse and improve public safety. Apelo Consulting | Page 3 Apelo Consulting | Page 9

  10. Key Players & Future Outlook Leaders and growth opportunities to 2032 Major Companies Thermo Fisher Scientific Diagnostics & lab solutions Abbott Laboratories Rapid & lab diagnostics Siemens Healthcare Immunoassay analyzers Roche IVD & clinical testing Emerging Opportunities Expanded workplace programs and compliance screening. Growth in point-of-care and home OTC testing. Wider adoption of hair testing for long-term use detection. Analytics and workflow automation; regulatory harmonization. Quest Diagnostics Reference lab services Closing statement: Sustained, regulation-led growth with technology-enabled expansion through 2032. LabCorp Lab-based testing Forecast: Market to reach ~US$ 11,715M by 2032 Apelo Consulting | Page 3 Apelo Consulting | Page 10

More Related